ABSTRACT
OBJECTIVE: To explore the effects of desloratadine citrate disodium on the postoperative complications and inflammatory markers in patients with chronic sinusitis undergoing endoscopic sinus surgery. METHODS: From June 2019 to December 2020, the patients with chronic sinusitis who received treatment in our hospital were selected and divided into the control group (CG) and experimental group (EG). In both groups, patients were given endoscopic sinus surgery. On this basis, patients were treated with desloratadine citrate disodium in the EG. The total effective rate of the operation and the incidence of complications were compared between the two groups, and the VAS scores of clinical symptoms were compared between the two groups after treatment. Meanwhile, the changes of serum TIgE, ECP and inflammatory factors were compared between the two groups, and the nasal mucociliary clearing function was compared between the two groups before and after treatment. RESULTS: After treatment, the total effective rate was 94.9% in the EG, which was significantly higher than that in the CG (82.2%). The levels of serum interleukin-6 (IL-6), interleukin-8 (IL-8), high-sensitivity C-reactive protein (hs-CRP) and tumor necrosis factor-α (TNF-α) in the EG were significantly lower than those in the CG, and the levels of serum TIgE and ECP were also significantly lower than those in the CG. After treatment for 3 months, the mucociliary clearance rate and mucociliary clearance rate in the EG were significantly higher than those in the CG, while the saccharin clearance time was significantly shorter than that in the CG. The incidence of complications in the EG was significantly lower than that in the CG (all P < 0.05). CONCLUSION: Desloratadine citrate disodium combined with endoscopic sinus surgery can improve the clinical efficacy, reduce the level of inflammatory factors and effectively reduce the incidence of complications in patients with chronic sinusitis.
ABSTRACT
This experiment was performed to explore the effect of oral desloratadine citrate disodium combined with physiological seawater nasal irrigation in the treatment of intermittent allergic rhinitis and its effect on serum inflammatory factors and peripheral blood Th1 and Th2. For this purpose, 100 patients of intermittent allergic rhinitis admitted to our hospital from January 2018 to January 2020. Randomly divided into a control group (n=50) and an observation group (n=50). The control group was given oral desloratadine citrate disodium. The observation group was given physiological seawater nasal irrigation based on the control group. Both groups were treated for one month. Compare the effect of treatment, symptom and sign scores pre and posttreatment, serum immunoglobulin E (IgE) levels, serum interleukin 4 (IL-4), IL-6, IL-13 and interferon-gamma (IFN-γ) levels, peripheral blood helper T cells 1 (Th1) and Th2 and the recurrence rate of patients after 1 year between two groups. Results showed that after one month of continuous treatment, the total effective rate of the observation group was significantly higher than that of the control group (P <0.05). The symptoms and signs scores and serum IgE levels of the two groups pretreatment (before treatment) were not significantly different (P > 0.05). The symptoms and signs scores and serum IgE levels of the two groups decreased significantly posttreatment (after treatment) (P <0.05), and the observation group was significantly lower than the control group (P <0.05). Pretreatment, the levels of serum inflammatory factors (IL-4, IL-6, IL-13, and IFN-γ) and the ratio of peripheral blood Th1 and Th2 to CD4+T cells were not significantly different (P> 0.05). After one month of continuous treatment, the levels of serum IL-4, IL-6, IL-13, and the ratio of peripheral blood CD4+IL-4+/CD4+ in the observation group and the control group were significantly reduced and the ratio of CD4+IFN-γ+/CD4+ was significantly increased (P <0.05). Compared with the control group, those changes were more obvious in the observation group (P <0.05). The one-year recurrence rate of the observation group was 4% (2/50), which was significantly lower than that of the control group, which was 20% (10/50). There was a statistical difference between the two groups (P <0.05). It was concluded that oral desloratadine citrate disodium combined with physiological seawater nasal irrigation can effectively improve the symptoms and signs of intermittent allergic rhinitis and reduce the recurrence rate. This may be related to balancing T cell responses, promoting systemic Th1 responses and inhibiting Th2 responses, and down-regulating inflammatory response.
Subject(s)
Immunoglobulin E/metabolism , Interferon-gamma/metabolism , Interleukin-13/metabolism , Interleukin-4/metabolism , Interleukin-6/metabolism , Loratadine/analogs & derivatives , Rhinitis, Allergic/drug therapy , Adult , CD4-Positive T-Lymphocytes/drug effects , CD4-Positive T-Lymphocytes/metabolism , Citric Acid/therapeutic use , Female , Humans , Loratadine/therapeutic use , Male , Nasal Lavage/methods , Rhinitis, Allergic/metabolism , SeawaterABSTRACT
Objective To compare the efficacy of desloratadine citrate disodium versus loratadine in the treatment of chronic urticaria (CU),and to evaluate their effect on serum interleukin (IL)-23,IL-33 and pulmonary and activation-regulated chemokine/CC chemokine ligand 18 (PARC/CCL-18).Methods From January 2013 to December 2016,120 CU patients treated in Department of Dermatology,Wuwei Oncology Hospital were enrolled into this study,and divided into study group and control group by using a random number table.Patients in the study group took oral desloratadine citrate disodium tablets 8.8 mg once a day,and patients in the control group took loratadine tablets 10 mg once a day.The treatment lasted 28 days.The therapeutic effect was compared between the two groups,and changes in serum levels of IL-23,IL-33 and PARC/CCL-18 were compared before and after treatment.Statistical analysis was carried out by using two-sample t test and chi-square test for comparing indices between the two groups.Results The response rate was significantly higher in the study group (88.33％,53/60) than in the control group (61.67％ [37/60],x2 =15.352,P ＜ 0.01).After the treatment,the serum levels of IL-23,IL-33 and PARC/CCL-18 in the study group significantly decreased to 87.72 ± 22.16 ng/L,95.94 ± 18.27 ng/L,85.93 ±27.34 μg/L respectively,which were all lower than those in the control group (104.21 ± 32.05 ng/L,106.27 ±20.93 ng/L,95.72 ± 30.28 μg/L,respectively;t =3.264,4.034,3.934,respectively,P =0.020,0.006,0.015,respectively).No significant difference was observed in the incidence of adverse reactions between the study group and control group (P =0.298).Conclusion Desloratadine citrate disodium can markedly improve the clinical symptoms of CU with favorable safety,likely by inhibiting the immune response of the body and reducing the effect of chemokines on the chemotaxis of inflammatory cells.
ABSTRACT
Objective To compare the efficacy and adverse reactions of desloratadine citrate disodium tablets and loratadine dispersible tablets in treatment of patients with allergic rhinitis,and their influence on leukotriene B4(LTB4),interleukin-4 (IL-4),interleukin-10 (IL-10) and interferon gamma (INF-γ).Methods From June 2015 to June 2016,a total of 110 patients with allergic rhinitis in the Second People's Hospital of Cangnan County were selected and randomly divided into control group and observation group according to the digital table,with 55 cases in each group.The control group was given loratadine dispersible tablets,while the observation group was given desloratadine citrate disodium tablets.Both two groups were treated for 14 days.The clinical efficacy,adverse reactions and changes of LTB4,IL-4,IL-10,INF-γ levels before and after treatment were compared between the two groups.Results The total effective rate of the observation group was 94.5 ％,which was significantly higher than 80.0％ of the control group(x2 =6.310,P ＜ 0.05).The incidence rate of adverse reactions in the observation group was 16.4％,which was similar to 20.0％ in the control group.Before treatment,there were no statistically significant differences in LTB4,IL-4,IL-10,INF-γ levels between the two groups (all P ＞ 0.05).After 2 weeks of treatment,the levels of LTB4,IL-4,IL-10 and INF-γ in the observation group were (67.74 ±10.15) ng/L,(52.37 ± 5.12) μg/L,(81.26 ± 11.78) μg/L,(94.47 ± 7.87) μg/L,respectively,which in the control group were (80.32 ± 9.97) ng/L,(62.95 ± 5.45) μg/L,(96.32 ± 11.57) μg/L,(86.74 ± 7.63) μg/L,respectively,there were statistically significant differences between the two groups (t =7.124,5.262,4.654,3.718,all P ＜ 0.05).Conclusion Both desloratadine citrate disodium tablets and loratadine dispersible tablets can effectively treat patients with allergic rhinitis,improve the symptoms and physical signs,reduce the levels of LTB4,IL-4 and IL-10,increase the level of INF-γ,and the adverse reactions are less and slight,but the efficacy of desloratadine citrate disodium tablets is better than loratadine dispersible tablets.
ABSTRACT
Objective To analyze the clinical efficacy of desloratadine citrate disodium and fexofenadine in the treatment of refractory urticaria . Methods 100 patients with refractory urticaria were randomly divided into observation group and control group according to the digital table method, with 50 cases in each group.The control group were treated with desloratadine citrate disodium, and the observation group were treated with fexofenadine on the basis of control group.The efficacy, immunity function ( CD3 +, CD4 +, CD4 +/CD8 +) , the changes of inflammatory factors [ procalcitonin ( PCT) , C-reactive protein ( CRP) ] and the quality of life were compared between the two groups.The adverse reaction rate in two groups was recorded in two groups.Results The total efficacy in observation group (88.0%) was significantly higher than that in control group (72.0%)(P<0.05).The indicators of immunity function in observation group were significantly higher than those in control group(P<0.05).The inflammatory factors in observation group were significantly lower than those in control group ( P<0.05 ) .The sleep and exercise quality rate of the observation group were significantly higher than those in control group(86.0% vs.68.0%,84.0% vs.66.0%,P<0.05).Conclusion The combination of desloratadine citrate disodium and fexofenadine in the treatment of refractory urticaria has a good effect, can effectively improve the immune function, reduce the secretion of inflammatory factors, thus effectively relieve the clinical symptoms, improve their quality of life, and has high security.
ABSTRACT
Objective To investigate the effect ofYupingfeng granule combined with Desloratadine Citrate Disodium tablets on the clinical efficacy and immune function in patients with allergic rhinitis.Methods A total of 112 patients with allergic rhinitis were randomly divided into two groups according to their order of treatment. The patients in the control group (n=56) were treated with Desloratadine Citrate Disodium tablets, and the patients in the experimental group (n=56) were treated withYupingfeng granule and Desloratadine Citrate Disodium tablets. The efficacy of clinical, the rate of adverse reaction, the improvement of immune and the rate of recurrence were compared between the two groups. Results The total effective rate of the experimental group was 94.64%, it is higher than the control group 85.71%, and the difference was statistically significant (Z=-3.254,P<0.01). After the treatment, runny nose (1.2 ± 0.1vs. 2.0 ± 0.2,t=6.420), nasal itching (1.2 ± 0.3vs. 1.7 ± 0.3,t=7.003), sneezing (0.8 ± 0.1vs. 1.3 ± 0.1,t=6.716), stuffy nose (1.1 ± 0.1vs. 1.6 ± 0.3,t=7.256)scores in the experimental group were significantly lower than those in the control group (P<0.05). There was no significant difference in the total IgE (114.48 ± 9.85 IU/mlvs. 130.64 ± 10.51 IU/ml,t=6.994) and VCAM-1(512.56 ± 13.84 μg/Lvs. 624.98 ± 7.06 μg/L,t=7.803) between the two groups (P<0.05). The levels of IL-4(16.25 ± 1.53 ng/Lvs. 22.38 ± 3.16 ng/L,t=5.458), IL-10 (15.98 ± 2.43 ng/Lvs. 21.82 ± 1.75 ng/L, t=6.149), LTB4 (59.14 ± 0.96 ng/Lvs. 67.46 ± 3.04 ng/L,t=5.342) in the experimental group were significantly lower than those in the control group (P<0.05). Six-month after the treatment, the relapse rate of the experimental group was 5.36%, while the control group was 16.07%, and the difference between two groups were significant (P<0.05).Conclusions The combination ofYupingfeng granule and Desloratadine Citrate Disodium tablets in the treatment of allergic rhinitis can significantly improve the clinical symptoms, adjust the immune function and reduce the recurrence of the disease.
ABSTRACT
Objective To investigate the effect ofYupingfeng granule combined with Desloratadine Citrate Disodium tablets on the clinical efficacy and immune function in patients with allergic rhinitis.Methods A total of 112 patients with allergic rhinitis were randomly divided into two groups according to their order of treatment. The patients in the control group (n=56) were treated with Desloratadine Citrate Disodium tablets, and the patients in the experimental group (n=56) were treated withYupingfeng granule and Desloratadine Citrate Disodium tablets. The efficacy of clinical, the rate of adverse reaction, the improvement of immune and the rate of recurrence were compared between the two groups. Results The total effective rate of the experimental group was 94.64%, it is higher than the control group 85.71%, and the difference was statistically significant (Z=-3.254,P<0.01). After the treatment, runny nose (1.2 ± 0.1vs. 2.0 ± 0.2,t=6.420), nasal itching (1.2 ± 0.3vs. 1.7 ± 0.3,t=7.003), sneezing (0.8 ± 0.1vs. 1.3 ± 0.1,t=6.716), stuffy nose (1.1 ± 0.1vs. 1.6 ± 0.3,t=7.256)scores in the experimental group were significantly lower than those in the control group (P<0.05). There was no significant difference in the total IgE (114.48 ± 9.85 IU/mlvs. 130.64 ± 10.51 IU/ml,t=6.994) and VCAM-1(512.56 ± 13.84 μg/Lvs. 624.98 ± 7.06 μg/L,t=7.803) between the two groups (P<0.05). The levels of IL-4(16.25 ± 1.53 ng/Lvs. 22.38 ± 3.16 ng/L,t=5.458), IL-10 (15.98 ± 2.43 ng/Lvs. 21.82 ± 1.75 ng/L, t=6.149), LTB4 (59.14 ± 0.96 ng/Lvs. 67.46 ± 3.04 ng/L,t=5.342) in the experimental group were significantly lower than those in the control group (P<0.05). Six-month after the treatment, the relapse rate of the experimental group was 5.36%, while the control group was 16.07%, and the difference between two groups were significant (P<0.05).Conclusions The combination ofYupingfeng granule and Desloratadine Citrate Disodium tablets in the treatment of allergic rhinitis can significantly improve the clinical symptoms, adjust the immune function and reduce the recurrence of the disease.
ABSTRACT
Objective To observe and analyze curative efficacy of Desloratadine Citrate Disodium in combination with endoscopic sinus surgery and its effects on serum TIgE, ECP and inlfammatory factors in patients with chronic sinusitis.Methods 90 patients with chronic sinusitis who received therapy in our hospital from January 2015 to June 2016 were collected as research objects to be randomly divided into the control group and the observation group equally. The control group was given endoscopic sinus surgery, and the observation group was given Desloratadine Citrate Disodium in combination with endoscopic sinus surgery. Then, visual analogue scale (VAS) was applied to assess the severity of subjective symptoms of the disease. Three months after the surgery, the curative efifcacy, scores of visual analogue scale (VAS) relfecting clinical symptoms, levels of serum TIgE, ECP and inlfammatory factors were compared between the two groups.Results All patients undergone successful surgery. The observation group had a total therapeutic efifciency ratio of 95.6%, which was signiifcantly higher than that of 82.2% in the control group (P < 0.05). In comparison with the control group, the observation group had lower VAS scores of nasal discharge, nasal obstruction, cheek pain, headache, hyposmia [(1.84 ± 0.89) vs (3.12 ± 1.03) points, (1.87 ± 0.81) vs (2.55 ± 1.14) points, (1.24 ± 0.86) vs (1.88 ± 0.79) points, (1.15 ± 0.54) vs (1.97 ± 0.83) points, (1.84 ± 0.73) vs (2.18 ± 0.84) points], lower levels of serum TIgE, ECP [(58.62 ± 7.36) vs (64.39 ± 7.18) kU/L, (4.25 ± 0.84) vs (5.01 ± 1.07) ng/L)] and inflammatory factors of TNF-α, IL-6, IL-8 [(1.27 ± 0.46) vs (2.62 ± 0.53) ng/ml, (5.13 ± 1.24) vs (9.54 ± 2.23) pg/ml, (282.63 ± 32.42) vs (315.84 ± 35.89) ng/L)] with statistical differences (allP < 0.05).Conclusion Desloratadine Citrate Disodium in combination with endoscopic sinus surgery is effective for chronic sinusitis, which can signiifcantly relieve clinical symptoms, reduce levels of serum TIgE, ECP and alleviate inlfammatory reaction.
ABSTRACT
Objective To analyze the clinical efficacy and adverse reactions of desloratadine citrate decre-mental therapy in treatment of chronic urticaria.Methods 162 cases of patients with chronic urticaria were selected, they were randomly divided into observation group and control group.Control group was given routine treatment of desloratadine citrate capsule,while the observation group was given desloratadine citrate capsule decreasing therapy, the therapeutic effect and the levels of serum immunoglobulins were compared between the two groups.Results After treatment,the total effective rate of the observation group was 95.06%,there was no significant difference compared with 92.59% of the control group (χ2 =3.254,P >0.05);Two weeks and four weeks after treatment,IgE levels were significantly lower than before treatment,there were significant difference (t =8.291,7.931,6.936,5.152,all P 0.05).The recurrence rate in the treatment group was 19.75%,which was significantly lower than the 40.74% of the control group,the difference between the two groups was statistically signif-icant (χ2 =6.914,P 0.05).Conclusion Desloratadine citrate capsules in treatment of chronic urticaria can not only obtain more effective clinical curative effect,but also has less toxic side effect.For the purposes of the application method of the drug,decreasing method compared with conventional medication therapy can effectively improve the level of serum IgE.Therefore,it is worthy of clinical application.
ABSTRACT
Chemokines have chemotactic properties on leukocyte subsets whose modulation plays a pivotal role in allergic inflammatory processes. Our present study was designed to investigate the anti-allergic and anti-inflammatory properties of desloratadine citrate disodium injection (DLC) and elucidate the molecular mechanisms of its anti-inflammatory properties. The anti-allergic effects of DLC were evaluated based on allergic symptoms, serological marker production and histological changes of the nasal mucosa in guinea pigs model of allergic rhinitis. The anti-inflammatory properties and molecular mechanisms of DLC were explored by studying the regulation of a set of chemokines and extracellular signal-regulated kinase (ERK)1/2 and nuclear factor-kappa B (NF-κB) pathways, after DLC treatment in guinea pigs model of allergic rhinitis in vivo and histamine-activated human nasal epithelial cells (HNECs) in vitro. In vivo model in guinea pigs, DLC alleviated the rhinitis symptoms, inhibited inflammatory cells infiltration in nasal lavage fluid (NLF) and histamine, monocyte chemotactic protein (MCP)-1, regulated on activation normal T cell expressed, and presumably secreted (RANTEs) and interleukin (IL)-8 release in sera and P-ERK1/2 and NF-κB activation in nasal mucosa. In vitro, DLC markedly inhibited histamine-induced production of MCP-1, RANTEs and IL-8 and suppressed c-Raf, mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) and ERK1/2 activation in HNECs. These results provide evidence that DLC possesses potent anti-allergic and anti-inflammatory properties. The mechanism of action underlying DLC in allergic inflammation appears to be inhibition of the phosphorylation of ERK1/2, in addition to blocking of the NF-κB pathway.
Subject(s)
Chemokines/biosynthesis , Epithelial Cells/drug effects , Epithelial Cells/metabolism , Extracellular Signal-Regulated MAP Kinases/metabolism , Loratadine/analogs & derivatives , NF-kappa B/metabolism , Nasal Mucosa/drug effects , Rhinitis, Allergic/blood , Animals , Anti-Allergic Agents/pharmacology , Cells, Cultured , Chemokine CCL2/blood , Chemokine CCL5/blood , Chemokines/blood , Disease Models, Animal , Epithelial Cells/enzymology , Guinea Pigs , Histamine/blood , Histamine/immunology , Histamine H1 Antagonists/administration & dosage , Histamine H1 Antagonists/pharmacology , Histamine H1 Antagonists/therapeutic use , Humans , Injections , Interleukin-8/blood , Loratadine/administration & dosage , Loratadine/pharmacology , Loratadine/therapeutic use , Nasal Lavage Fluid/cytology , Nasal Mucosa/metabolism , Ovalbumin/immunology , Rhinitis, Allergic/drug therapy , Rhinitis, Allergic/immunology , Signal Transduction/drug effectsABSTRACT
BACKGROUND: Allergic rhinitis (AR) is a very common worldwide problem; patients display a number of symptoms, such as sneezing, nasal itching, and rhinorrhea, and their lifestyle is affected. Desloratadine is a novel, long-acting inhibitor of histamine. However, very little is known about the effect of desloratadine citrate disodium injection (DLC injection) on AR, and the underlying mechanisms are yet unexplored. Herein, we sought to explore the effects and mechanisms of actions of DLC injection in ovalbumin (OVA)-induced immune responses in a rat model of AR. METHODS: Sixty rats were subjected to immunization with OVA (intraperitoneal [i.p.]), followed by a nasal challenge with OVA. Drugs or saline were given daily for treatment. Nasal symptoms and histology of the nasal mucosa were examined. Cytokines such as interleukin (IL)-4, IL-12, interferon (IFN)-γ, adhesion molecules such as soluble vascular cell adhesion molecule 1 (sVCAM-1), and inducible nitric oxide synthase (iNOS) expression were assessed by enzyme-linked immunosorbent assay (ELISA) kit. Nitric oxide (NO) concentration was also measured by NO assay kit. RESULTS: DLC treatment (intravenous [i.v.]) significantly decreased the frequency of sneezing and nasal scratching and alleviated nasal inflammation by increasing the serum levels of IFN-γ and IL-12, while lowering the expression of IL-4. Thus, DLC (i.v.) treatment led to a marked elevation in T-helper 1/T-helper 2 (Th1/Th2) ratio when administered in the AR rats. The expression of sVCAM-1, iNOS, and NO were also reversed. CONCLUSION: DLC (i.v.), given after an allergen challenge, improved Th1 cytokines level and restrained Th2 responses alleviating the symptoms of AR. Our results indicate that DLC injection may exhibit such effects through the modulation of T-cell responses.
Subject(s)
Citrates/administration & dosage , Histamine Antagonists/administration & dosage , Loratadine/analogs & derivatives , Rhinitis, Allergic/drug therapy , T-Lymphocytes/drug effects , Allergens/immunology , Animals , Cell Adhesion Molecules/genetics , Cell Adhesion Molecules/metabolism , Citrates/adverse effects , Citrates/chemistry , Cytokines/genetics , Cytokines/metabolism , Disease Models, Animal , Gene Expression Regulation , Histamine Antagonists/adverse effects , Histamine Antagonists/chemistry , Humans , Immunomodulation , Loratadine/administration & dosage , Loratadine/adverse effects , Loratadine/chemistry , Nitric Oxide Synthase Type II/genetics , Nitric Oxide Synthase Type II/metabolism , Ovalbumin/immunology , Rats , Rhinitis, Allergic/immunology , Sodium Citrate , T-Lymphocytes/immunology , Th1-Th2 Balance/drug effectsABSTRACT
The present study, demonstrates that, desloratadine citrate disodium injection (DLC) possesses antihistaminic, anti-allergic and anti-inflammatory properties and elucidates its molecular mechanisms of anti-inflammatory properties. In vitro antihistamine activity of DLC was determined in guinea pig isolated tissues. In vivo antihistamine effects were evaluated after following intravenous administration of DLC in mice with histamine- induced paw edema and in rats with increased capillary permeability. Anti-allergic effects were assessed through passive cutaneous anaphylactic (PCA) reactions in sensitized rodents and ovalbumin-induced allergic rhinitis in rats. Anti-inflammatory properties and molecular mechanisms of DLC were determined on histamine- and lipopolysaccharide (LPS)-induced EA.hy926 endothelial cells. DLC exhibited significant and reversible inhibition of histamine-induced contractions of isolated guinea pig ileum with pA2 value of 8.88. Histamine-induced paw edema and increased capillary permeability were notably inhibited by DLC intravenous administration. In the model of PCA reactions, DLC showed significant activity in a dose-dependent nd potently inhibited both the early-phase and late-phase allergic reaction of ovalbumin-induced allergic rhinitis in rats. DLC alleviated the rhinitis symptoms and inhibited inflammatory cell infiltration, IL-4 and protein leakage in nasal lavage fluid (NLF). In EA.hy926 cells, DLC significantly inhibited the histamine- and LPS- induced IL-6 and IL-8 production and P-selectin and intercellular cell adhesion molecule-1 (ICAM-1) expression. Moreover, DLC reduced translocation of nuclear factor-kappaB (NF-κB) to the nucleus in activated EA.hy926 cells. These results provide evidence that DLC possesses potent antihistaminic, anti-allergic and, anti-inflammatory properties via suppressing IL-6, IL-8, P-selectin and ICAM-1 expression.
Subject(s)
Anti-Allergic Agents/pharmacology , Anti-Inflammatory Agents/pharmacology , Endothelial Cells/drug effects , Histamine H1 Antagonists/pharmacology , Loratadine/analogs & derivatives , Animals , Anti-Allergic Agents/therapeutic use , Anti-Inflammatory Agents/therapeutic use , Capillary Permeability/drug effects , Cell Survival , Chlorpheniramine/pharmacology , Chlorpheniramine/therapeutic use , Edema/chemically induced , Edema/drug therapy , Endothelial Cells/metabolism , Guinea Pigs , Histamine/pharmacology , Histamine H1 Antagonists/therapeutic use , Humans , Inflammation Mediators/metabolism , Loratadine/pharmacology , Loratadine/therapeutic use , Male , Mice , Nasal Mucosa/drug effects , Nasal Mucosa/metabolism , Passive Cutaneous Anaphylaxis/drug effects , Rats , Rhinitis/chemically induced , Rhinitis/drug therapyABSTRACT
Objective To evaluate the efficacy and safety of desloratadine citrate disodium versus epinastine for the treatment of chronic urticaria (CU).Methods A randomized,double-blind,double-dummy controlled clinical trial was conducted.Patients with CU were divided into test group and control group to be treated by oral desloratadine citrate disodium (8.8 mg/d) and epinastine (10 mg/d) respectively once a day for 28 days.All the patients were followed up after starting treatment.Therapeutic effect was evaluated,and adverse reactions were observed.Results One hundred and fifty-seven patients were enrolled in this study,and 142 patients were valid for evaluation of efficacy and safety at the end of study.After treatment for 28 days,there was no significant difference between the test group and control group in response rate (81.16 ％ vs.78.08 ％,P ＞ 0.05) or incidence rate of adverse reactions (13.89 ％ vs.12.16 ％,P＞ 0.05).Conclusion Desloratadine citrate disodium is effective and safe for the treatment of CU.
ABSTRACT
Objective To observe the clinical efficacy of desloratadine citrate disodium tablets combined with narrow band ultraviolet B in the treatment of pityriasis rosea.Methods According to the digital table,88 pityriasis rosea patients were randomly divided into the two groups.45 cases of the study group were treated by desloratadine citrate disodium tablets combined with narrow ultraviolet B,43 cases of the control group were treated by desloratadine citrate disodium tablets alone.The both two groups applied Binghuangfule cream.The therapeutic effect and safety of the two groups were compared.Results The cure rate in study group was 71.11％,which of the control group was 51.16％,the difference was not statistically significant (x2 =3.69,P ＞ 0.05).The effective rate of the treatment group was 91.11％,which of the control group was 69.77％,the difference between the two groups was statistically significant (x2 =6.43,P ＜ 0.05).Conclusion The result reveals that desloratadine citrate disodium tablets combined with narrow band ultraviolet B is more effective and worthy to be used in clinical practice.
ABSTRACT
OBJECTIVE:To compare the efficacy and safety of desloratadine citrate disodium and acrivastine decremental thera-py in the treatment of chronic urticaria. METHODS:132 patients with chronic urticaria were randomly divided into group A(62 cases)and group B(70 cases). Group A was orally given 8.8 mg Desloratadine citrate disodium tablet in 12 2 weeks,once a day;8.8 mg in 3-4 weeks,once every 2 days;8.8 mg in 5-6 weeks,once every 3 days;8.8 mg in 7-8 weeks,once every 4 days;and 8.8 mg in 9-10 weeks,once every 5 days. Group B was orally given 8 mg Acrivastine capsule in 12 2 weeks,3 times a day;8 mg in 3-4 weeks,twice a day;8 mg in 5-6 weeks,once a day;8 mg in 7-8 weeks,once every 2 days;and 8 mg in 9-10 weeks, once every 3 days. The treatment course for both groups was 10 weeks. Clinical efficacy,and plasma histamine levels and total scores of signs and symptoms before and after treatment in 2 groups were observed,and recurrence and incidence of adverse reac-tions after 4 weeks of stopping drugs in 2 groups were followed-up. RESULTS:There were no significant difference in the total ef-fective rate and incidence of adverse reactions between 2 groups(P>0.05). After treatment,the total scores of signs and symptoms in 2 groups were significantly lower than before,the difference was statistically significant(P0.05). The recurrence rate in group A was significantly lower than group B,the difference was sta-tistically significant(P<0.05). CONCLUSIONS:Both efficacy and safety of desloratadine citrate disodium and acrivastine decre-mental therapy in the treatment of chronic urticaria are good,however,desloratadine citrate disodium is better than acrivastine in re-ducing recurrence rate.
ABSTRACT
OBJECTIVE:To observe the clinical efficacy and safety of the effect of desloratadine citrate disodium in the decre-mental treatment of chronic urticaria. METHODS:212 patients with chronic urticaria were randomly divided into decremental treat-ment group and control group. Decremental treatment group was treated with Desloratadine citrate disodium capsules 17.6 mg in the first week,orally,qd;8.8 mg in the second week,orally,qd;8.8 mg in the third week,orally,qod;and 8.8 mg in the fourth week,orally,q3d. Control group was treated with Desloratadine citrate disodium capsules 8.8 mg,orally,qd. The treatment course for both groups was 4 weeks. The clinic data was observed,including clinical efficacy,and serum IgE,clinical symptom scores before and after treatment,recurrence rate and incidence of adverse reactions. RESULTS:The differences were not statistical-ly significant in the total effective rate and incidence of adverse reactions between 2 groups(P>0.05). The recurrence rate in decre-mental treatment was significantly lower than control group(P0.05). CONCLUSIONS:Desloratadine citrate disodium have similar clinical efficacies and safety in the decremental treatment and conventional treatment of chronic urticaria. However,decremental treatment of deslo-ratadine citrate disodium is better than conventional treatment in terms of improving the level of IgE.
ABSTRACT
Objective:To observe the clinical effect and safety of desloratadine citrate disodium in the treatment of allergic rhinitis ( AR) . Methods:Totally 80 patients were randomly divided into the control group and the observation group with 40 ones in each. There was no difference in gender, age, duration of allergic rhinitis, classification of serological specificity IgE between the two groups (P>0. 05). The observation group was treated with desloratadine citrate disodium tablets 8. 8mg, po, qd. The control group was given loratadine 10mg, po, qd. The treatment course was 12 days. All the patients were not given corticosteroids and other antihistamines. The clinical symptoms and signs integral, curative effect and adverse drug reactions during the treatment were observed. Results: In the observation group, 23 cases were markedly effective, 13 cases were effective, 3 cases were ineffective, one case didn’ t finish the study, and the total effective rate was 92. 30%. In the control group, the above index was 10 cases, 18 cases, 10 cases, 2 cases and 73. 68%, respectively. There was statistically significant difference in the total effective rate between the two groups (P<0. 05). The symptoms and signs integral after the treatment in the observation group was significantly decreased compared with that in the control group, and the difference was statistically significant (P<0. 05). The incidence of adverse drug reactions in the observed group was obviously lower than that in the control group. Conclusion:Compared with that of loratadine, the clinical efficacy of desloratadine cit-rate disodium tablets is better in the treatment of AR with good safety.
ABSTRACT
Objective To investigate the curative effect of Suhuangzhike capsules and Desloratadine Citrate Disodium used in chronicity allergic pharyngits .Methods Branched 147 patients into two sets ,the observation group with 85 patients treated with Suhuangzhike capsules and Desloratadine Citrate Disodium ,the control group with 62 pa-tients treated with Desloratadine Citrate Disodium only .Results The total effective rate of the observation group was 97.6%.The total effective rate of the control group was 75.8%,with statistical significance(χ2 =14.25,P<0.05). Follow up in 6 ~8 weeks,relapse rate of the observation group was 14.1%,relapse rate of the control group was 37.1%,with statistical significance(χ2 =10.53,P<0.05).Conclusion Suhuangzhike capsules and Desloratadine Citrate Disodium has good curative effect used in chronicity allergic pharyngits ,which can be decreased relapse .
